Reichardt, Peter <br/><br/>
Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting.  [electronic resource] 

 -  Oncology research and treatment  2019 
 - 629-635 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>2296-5262 
<br/><br/><label>Standard No.: </label>10.1159/000502749  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Chemotherapy, Adjuvant<br/>Female<br/>Gastrointestinal Neoplasms--drug therapy<br/>Gastrointestinal Stromal Tumors--drug therapy<br/>Humans<br/>Imatinib Mesylate--administration & dosage<br/>Male<br/>Middle Aged<br/>Protein Kinase Inhibitors--administration & dosage<br/>Survival Analysis<br/>Treatment Outcome<br/>Young Adult